<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>A1838</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 6 4 5 2 3 4;}
@font-face
	{font-family:Albertus;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:9.0pt;
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.PrefileFronterTitle, li.PrefileFronterTitle, div.PrefileFronterTitle
	{mso-style-name:PrefileFronterTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.StylePrefileFronterTitleLeft, li.StylePrefileFronterTitleLeft, div.StylePrefileFronterTitleLeft
	{mso-style-name:"Style PrefileFronterTitle + Left";
	margin-top:0in;
	margin-right:-.2in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times",serif;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.Superscript
	{mso-style-name:Superscript;
	font-family:"Albertus",sans-serif;
	font-weight:bold;
	vertical-align:super;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.amendfooter, li.amendfooter, div.amendfooter
	{mso-style-name:amendfooter;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.5in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 1.2in 2.0in;}
div.WordSection3
	{page:WordSection3;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuBill><a name=bpuFrontPg></a>ASSEMBLY, No. 1838 </p>

<p class=bpuWpGraphic></p>

<p class=bpuState>STATE OF NEW JERSEY</p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>PRE-FILED FOR INTRODUCTION IN THE 2024 SESSION</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Assemblywoman  SHANIQUE SPEIGHT</p>

<p class=bpuSponsor>District 29 (Essex and Hudson)</p>

<p class=bpuSponsor>Assemblywoman  JESSICA RAMIREZ</p>

<p class=bpuSponsor>District 32 (Hudson)</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Establishes New Jersey Active Pharmaceutical
Ingredient Regulatory Commission. </p>

<p class=bpuNormText>&nbsp;</p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     Introduced Pending Technical Review by Legislative
Counsel.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=HangingAnAct style='line-height:150%'><span class=BillHead>An Act</span><span
class=HangingAnActChar> establishing the New Jersey Active Pharmaceutical Ingredient
Regulatory Commission and supplementing Title 24 of the Revised Statutes.</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     1.    As used in this act:</p>

<p class=MsoNormal style='line-height:150%'>     Commission means the New
Jersey Active Pharmaceutical Ingredient Regulatory Commission.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     2.    The New Jersey Active
Pharmaceutical Ingredient Regulatory Commission is created and established in
the executive branch of the State Government.  For the purposes of complying
with the provisions of Article V, Section IV, paragraph 1 of the New Jersey
Constitution, the commission is allocated within the Department of the
Treasury, but notwithstanding this allocation, the commission shall be
independent of any supervision or control by the department or by any board or officer
thereof.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     3.    a.  The commission shall
consist of the following 17 members:</p>

<p class=MsoNormal style='line-height:150%'>     (1) four public members to be
appointed by the Governor, with the advice and consent of the Senate, with each
public member having a background in the field or business of pharmaceuticals,
one public member having a general background in pharmaceutical manufacturing,
and at least one public member having a background in active pharmaceutical
ingredient manufacturing; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   two public members to be
appointed by the Governor upon the recommendation of the President of the
Senate and two public members to be appointed by the Governor upon the
recommendation of the Speaker of the General Assembly, with each public member
having a background in the field or business of pharmaceuticals or active pharmaceutical
ingredient manufacturing;</p>

<p class=MsoNormal style='line-height:150%'>     (3)   two members of the Senate,
who shall not be of the same political party, to be appointed by the President
of the Senate and who shall serve as ex officio, non-voting members, and two
members of the General Assembly, who shall not be of the same political party,
to be appointed by the Speaker of the General Assembly and who shall serve as
ex officio, non-voting members;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   the Commissioner of
Health, ex officio, or the commissioner's representative;</p>

<p class=MsoNormal style='line-height:150%'>     (5)   the Executive Director
of the New Jersey Economic Development Authority, ex officio, or the executive
director's representative; </p>

<p class=MsoNormal style='line-height:150%'>     (6) the Executive Director of
the New Jersey Commission of Science, Innovation and Technology, ex officio, or
the executive director's representative; and   </p>

<p class=MsoNormal style='line-height:150%'>     (7)   two presidents of a
State public or private research institution of higher education, who shall be
appointed annually by the Governor and who shall serve as ex officio,
non-voting members.</p>

<p class=MsoNormal style='line-height:150%'>     b.    In the selection of
public members, a strong effort shall be made to appoint women and minorities
to the commission. </p>

<p class=MsoNormal style='line-height:150%'>     c.     The commission members
who are not members of the Senate or the General Assembly and who are not
presidents of a State public or private research institution of higher
education shall have a right to vote on various matters considered by the
commission.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     4.    a.  The terms of the
public members of the commission appointed by the Governor shall be for five
years or until their successors are appointed, except that of the appointments
first made to the commission:  three shall serve for three years or until their
successors are appointed, three shall serve for four years or until their
successors are appointed, and three shall serve for five years or until their
successors are appointed. Any vacancy shall be filled in the same manner as the
original appointment but only for the balance of the unexpired term. The
commission members shall serve without compensation but shall be reimbursed for
necessary expenses incurred in the performance of their duties, within the
limits of funds appropriated or otherwise made available to the commission for
its purposes.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Each member appointed by
the Governor may be removed from office by the Governor, for cause, after a
public hearing, and may be suspended by the Governor pending the completion of
the hearing.  Each member, before entering upon the member's duties, shall take
and subscribe an oath to perform the duties of the office faithfully,
impartially, and justly to the best of the member's ability. A record of these
oaths shall be filed in the office of the Secretary of State.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     5.    The Governor shall
designate the chair of the commission from among the public members appointed
by the Governor.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     6.    a.  The commission shall
appoint an executive director, who shall serve at the pleasure of the commission
and who shall receive compensation as provided by law.</p>

<p class=MsoNormal style='line-height:150%'>     b.    The executive director
shall be responsible for the selection of properly qualified staff members of
the commission.  Staff members shall have backgrounds in the field or business
of pharmaceuticals.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     7.    The commission shall:</p>

<p class=MsoNormal style='line-height:150%'>     a.     establish standards and
provide oversight of the manufacture <br clear=all style='page-break-before:
always'>
of active pharmaceutical ingredients in the State and for the quality and use
of active pharmaceutical ingredients manufactured outside of the State in a manner
that is consistent with federal law; </p>

<p class=MsoNormal style='line-height:150%'>     b.    promote the growth of
the active pharmaceutical ingredient manufacturing industry in this State, with
a focus on the use of available federal monies and resources;</p>

<p class=MsoNormal style='line-height:150%'>     c.     act as a liaison
between the pharmaceutical industry and the State and federal governments as it
pertains to identifying federal funding and grant opportunities for members of
the industry;  </p>

<p class=MsoNormal style='line-height:150%'>     d.    adopt rules and
regulations pursuant to the &quot;Administrative Procedure Act,&quot; P.L.1968,
c.410 (C.52:14B-1 et seq.) if necessary to effectuate the provisions of this
act;</p>

<p class=MsoNormal style='line-height:150%'>     e.     adopt, amend, and
repeal bylaws for the regulation of its affairs and the conduct of its
business;</p>

<p class=MsoNormal style='line-height:150%'>     f.     adopt and have a seal
and alter the same at its pleasure;</p>

<p class=MsoNormal style='line-height:150%'>     g.    have the authority to
sue and be sued;</p>

<p class=MsoNormal style='line-height:150%'>     h.    have the authority to
conduct meetings and public hearings in connection with the purposes of this
act;</p>

<p class=MsoNormal style='line-height:150%'>     i.     receive and disburse
funds from non-State sources including but not limited to federal funds; and</p>

<p class=MsoNormal style='line-height:150%'>     j.     have the authority to do
any and all things necessary or convenient to carry out its purposes and
exercise the powers granted in this act.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     8.    This act shall take
effect immediately.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:150%'>STATEMENT</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     This bill establishes the New
Jersey Active Pharmaceutical Ingredient Regulatory Commission (commission).</p>

<p class=MsoNormal style='line-height:150%'>     Under the bill, the commission
is to consist of the following 17 members:  (1) four public members to be
appointed by the Governor, with the advice and consent of the Senate, with each
public member having a background in the field or business of pharmaceuticals,
one public member having a general background in pharmaceutical manufacturing,
and at least one public member having a background in active pharmaceutical
ingredient manufacturing; (2) two public members to be appointed by the
Governor upon the recommendation of the President of the Senate and two public
members to be appointed by the Governor upon the recommendation of the Speaker
of the General Assembly, with each public member having a background in the
field or business of pharmaceuticals or active pharmaceutical ingredient
manufacturing; (3) two members of the Senate, who are not to be of the same
political party, to be appointed by the President of the Senate and <br
clear=all style='page-break-before:always'>
who are to serve as ex officio, non-voting members, and two members of the
General Assembly, who are not to be of the same political party, to be
appointed by the Speaker of the General Assembly and who is to serve as ex
officio, non-voting members; (4) the Commissioner of Health, ex officio, or the
commissioner's representative; (5) the Executive Director of the New Jersey
Economic Development Authority, ex officio, or the executive director's
representative; (6) the Executive Director of the New Jersey Commission of Science,
Innovation and Technology, ex officio, or the executive director's
representative; and (7) two presidents of a State public or private research
institution of higher education, who are to be appointed annually by the
Governor and who are to serve as ex officio, non-voting members.  In the
selection of public members, a strong effort is to be made to appoint women and
minorities to the commission. </p>

<p class=MsoNormal style='line-height:150%'>     Under the bill, the commission
is to:  (1) establish standards and provide oversight of the manufacture of
active pharmaceutical ingredients in the State and for the quality and use of
active pharmaceutical ingredients manufactured outside of the State in a manner
that is consistent with federal law; (2) promote the growth of the active pharmaceutical
ingredient manufacturing industry in this State, with a focus on the use of
available federal monies and resources; (3) act as a liaison between the pharmaceutical
industry and the State and federal governments as it pertains to identifying
federal funding and grant opportunities for members of the industry; (4) adopt
rules and regulations pursuant to the &quot;Administrative Procedure Act,&quot;
P.L.1968, c.410 (C.52:14B-1 et seq.) if necessary to effectuate the provisions
of this act; (5) adopt, amend, and repeal bylaws for the regulation of its
affairs and the conduct of its business; (6) adopt and have a seal and alter
the same at its pleasure; (7) have the authority to sue and be sued; (8) have
the authority to conduct meetings and public hearings in connection with the
purposes of this act; (9) receive and disburse funds from non-State sources
including but not limited to federal funds; and (10) have the authority to do
any and all things necessary or convenient to carry out its purposes and
exercise the powers granted in this act.</p>

<p class=MsoNormal style='line-height:150%'>     On February 24, 2021, the
Biden administration issued an executive order requiring the review of active pharmaceutical
ingredient supply chains.  The executive order directs a 100-day review and
strategy development process to identify and address vulnerabilities in the
supply chains of four key product sectors which are:  semiconductor manufacturing
and advanced packaging, large capacity batteries, critical minerals and
materials, and pharmaceuticals and active pharmaceutical ingredients.  With
regards &quot;to promot[ing] domestic growth, equity, and resilience <br
clear=all style='page-break-before:always'>
throughout the pharmaceutical&quot; and active pharmaceutical ingredient supply
chains, the executive order prescribes &quot;a strategic approach that includes
the following three elements[:]&quot; 1) boosting local production to foster
international competition; 2) building </p>

<p class=MsoNormal style='line-height:150%'>emergency capacity; and 3)
increasing information available to the Federal Drug Administration to improve
its surveillance and shortage prevention and mitigation efforts.  </p>

</div>

</body>

</html>
